Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities
Crossref DOI link: https://doi.org/10.1038/s41598-018-26187-w
Published Online: 2018-05-17
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Farrokhi, Vahid
Chabot, Jeffrey R.
Neubert, Hendrik
Yang, Zhiyong
Text and Data Mining valid from 2018-05-17
Version of Record valid from 2018-05-17
Article History
Received: 8 December 2017
Accepted: 8 May 2018
First Online: 17 May 2018
Competing Interests
: The authors declare no competing interests.